Abiopharma

A FDA dos EUA concede revisão prioritária ao TEVIMBRA da BeOne Medicines para o tratamento de primeira linha do adenocarcinoma gastroesofágico HER2+

LFDA statunitense concede la revisione prioritaria a TEVIMBRA di BeOne Medicines nel trattamento di prima linea delladenocarcinoma gastroesofageo HER2 positivo

Amerikaanse FDA kent Priority Review toe aan BeOne Medicines’ TEVIMBRA in eerstelijns HER2+ GEA

La FDA américaine accorde une évaluation prioritaire au TEVIMBRA de BeOne Medicines dans le traitement de première intention de l’adénocarcinome gastro-œsophagien HER2+

Die US-amerikanische FDA bewilligt die vorrangige Prüfung von TEVIMBRA von BeOne Medicines als Erstlinienbehandlung bei HER2+ GEA

Deadline Approaching: LKQ Corporation (LKQ) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Gartner, Inc. (IT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Mise à disposition du Document d’Enregistrement Universel 2025

Securities Fraud Investigation Into Regencell Bioscience Holdings Limited (RGC) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

New Era Energy & Digital, Inc. (NUAI) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit